Savara Inc.
General ticker "SVRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Savara Inc. follows the US Stock Market performance with the rate: 24.9%.
Estimated limits based on current volatility of 2.9%: low 4.88$, high 5.18$
Factors to consider:
- Total employees count: 70 (+18.6%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operating losses, Clinical trial failure, Regulatory and compliance, Funding shortfall, Manufacturing scale up
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.17$, 9.18$]
- 2026-12-31 to 2027-12-31 estimated range: [3.66$, 8.09$]
Financial Metrics affecting the SVRA estimates:
- Positive: with PPE of -11.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: 69.38 < Shareholder equity ratio, % of 80.15 <= 81.92
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -1.31 <= -1.23
Short-term SVRA quotes
Long-term SVRA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $60.01MM | $103.20MM | $123.55MM |
| Operating Income | $-60.01MM | $-103.20MM | $-123.55MM |
| Non-Operating Income | $5.31MM | $7.32MM | $4.71MM |
| R&D Expense | $44.26MM | $78.03MM | $81.40MM |
| Income(Loss) | $-54.70MM | $-95.88MM | $-118.84MM |
| Net Income(Loss)* | $-54.70MM | $-95.88MM | $-118.84MM |
| Stockholders Equity | $140.37MM | $171.45MM | $203.13MM |
| Assets | $177.56MM | $212.88MM | $253.44MM |
| Operating Cash Flow | $-51.06MM | $-89.09MM | $-101.04MM |
| Capital expenditure | $0.30MM | $0.03MM | $0.02MM |
| Investing Cash Flow | $-57.12MM | $-39.94MM | $-18.44MM |
| Financing Cash Flow | $82.78MM | $117.58MM | $137.81MM |
| Earnings Per Share** | $-0.33 | $-0.48 | $-0.53 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.